SAMUELE MARAMAI, PhD

INFORMAZIONI PERSONALI

Nazionalità	Italiana
Affiliazione	Dipartimento di Biotecnologie, Chimica e Farmacia – Università degli Studi di Siena Via Aldo Moro, 2 – 53100, Siena (SI) - Italy
Ufficio	(+39) 0577 232933 (int. 2933)
E-mail	samuele.maramai@unisi.it
ORCID	0000-0001-7499-6961
Web of Science Researcher ID	AAP-7585-2020
Website	https://docenti.unisi.it/it/maramai

POSIZIONE ATTUALE

Professore Associato in chimica organica

Istituzione	Università degli Studi di Siena
Azienda o settore	Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena

ATTIVITÀ DI RICERCA

Data	**2023-2026**
Istituzione	Università degli Studi di Siena
Azienda o settore	Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
Posizione	**Ricercatore Legge 240/10 tipo B**
Principali attività e responsabilità	- Analisi metabolimiche e lipidomiche su estratti da biomasse e matrici biologiche; - Sviluppo di nuove metodologie *green* assistite da microonde; - Design e sviluppo di profarmaci sensibili alla luce per il trattamento del cancro.

Data	**2020-2023**
Istituzione	Università degli Studi di Siena
Azienda o settore	Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
Posizione	**Assegnista di ricerca**
Principali attività e responsabilità	- **2021-2022**: sviluppo e caratterizzazione preclinica di composti selettivi per GLI per il trattamento di carcinomi a cellule basali e melanoma. - **2020**: sintesi e modificazioni strutturali di composti naturali citotossici.

Data	**2016-2019**
Istituzione	University of Sussex, Falmer, Brighton BN1 9RH, UK
Azienda o settore	Sussex Drug Discovery Centre (SDDC), School of Life Sciences
Posizione	**Research Fellow**
Principali attività e responsabilità	- **2018-2019**: an integrated drug discovery and validation platform for the identification of novel agents targeting DNA damage response for the treatment of cancer. - **2016-2018**: Valium without sedation. Design and synthesis of positive allosteric modulators of GABA-A receptors selective for α2/α3 subunits.

Data	**2013-2016**
Istituzione	Università degli Studi di Siena
Azienda o settore	Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
Posizione	**Ricercatore Post-Dottorato**
Principali attività e responsabilità	- **2016**: sintesi di molecole ad attività antitumorale. - **2014-2016**: sintesi di peptidomimetici e bioconiugati. - **2013-2014**: sintesi di molecole bioattive.

ATTIVITÀ DIDATTICA

Data a.a. 2025/2026
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
Corso **Advanced Organic Chemistry III – Catalysis: principle and laboratory practice** – Chemistry (LM-54, D628)

Data a.a. 2025/2026
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento di Ingegneria dell'informazione e scienze matematiche
Corso **Chemistry – Organic chemistry -** Biotech engineering for health (L2/L8, D625)

Data a.a 2025/2026 – a.a. 2024/2025 – a.a. 2023/2024
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento di Scienze della Vita, V. Aldo Moro 2, 53100 - Siena
Corso **Principi di chimica organica** – Scienze biologiche (SE001)

Data a.a. 2024/2025 – a.a. 2023/2024
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
Corso **Laboratorio di analisi organiche** – Scienze chimiche (SE002)

Data a.a. 2022/2023 – a.a. 2021/2022 – a.a. 2020/2021
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
Posizione **Professore aggregato (60 h)** – Analisi quantitativa dei farmaci – Farmacia (FF003)

DIDATTICA IN SCUOLE DI DOTTORATO

Data a.a. 2021/2022 – a.a. 2020/2021
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento di Biotecnologie, Chimica e Farmacia, V. Aldo Moro 2, 53100 - Siena
PhD program in Chemical and Pharmaceutical Science – Titolo del corso: "The chemistry of CNS modulators: valium without sedation" (8 h - 1 ECTS).

ISTRUZIONE

Data **2012**
Istituzione Università degli Studi di Siena
Azienda o settore Dipartimento Farmaco Chimico Tecnologico, Facoltà di Farmacia
Titolo **PhD in Pharmaceutical Sciences** (MIUR fellowship for PhD)

Data **2010**
Istituzione Università degli Studi di Siena – Via Banchi di Sotto 55, 53100 - Siena
Titolo **Master di II livello** in "Drug Design and Synthesis"

Data **2008**
Istituzione Università degli Studi di Siena – Via Banchi di Sotto 55, 53100 - Siena
Titolo **Laurea Specialistica** a normative UE in Chimica e Tecnologia Farmaceutiche *cum laude*.
Dicembre 2008: Esame di stato per l'abilitazione alla professione di Farmacista.

ALTRE COMPETENZE

Madrelingua Italiano

Altre lingue **English** (3.5 anni nel Regno Unito)

Certificati **First Certificate in English** (FCE) issued by University of Cambridge
Preliminary English Test (PET) issued by University of Cambridge

ABILITAZIONE SCIENTIFICA NAZIONALE

03/CHEM-05 Abilitazione Scientifica Nazionale alle funzioni di professore universitario di **II Fascia** nel Settore Concorsuale 03/C1 - CHIMICA ORGANICA.

03/CHEM-07 Abilitazione Scientifica Nazionale alle funzioni di professore universitario di **I Fascia** nel Settore Concorsuale 03/D1 - CHIMICA E TECNOLOGIE FARMACEUTICHE, TOSSICOLOGICHE E NUTRACEUTICO-ALIMENTARI

03/CHEM-07 Abilitazione Scientifica Nazionale alle funzioni di professore universitario di **II Fascia** nel Settore Concorsuale 03/D1 - CHIMICA E TECNOLOGIE FARMACEUTICHE, TOSSICOLOGICHE E NUTRACEUTICO-ALIMENTARI.

EDITORIA

Academic editor for Scientific Reports (2025, Springer)

Academic Editor for Bentham (2023) - Anti-Cancer Agents in Medicinal Chemistry (Thematic issue: Challenges in the use of aptamers for targeted anticancer therapy).

Academic Editor for BioMed Research International (2021-2025, Wiley)

Guest Editor for Pharmaceuticals (2024, MDPI). Special Issue "Hsp90 Inhibitors: Progress, Challenges, and Opportunities in Drug Discovery and Development"

Guest Editor for IJMS (2023, MDPI) – Small Molecules: From Design, Synthesis and Characterization to Pharmacological Functional Analysis.

Guest Associate Editor for Frontiers in Molecular Biosciences (2021/2022) – Research Topic: Modulators of 14-3-3 Protein-Protein Interactions involved in Cancer Pathology

Guest Editor for IJMS (2021, MDPI) – Special Issue: Recent Advances in the Identification of Biologically Active Natural and Synthetic Small Molecules

Guest Editor for BioMed Research International: Neurology (2019, HINDAWI) – Special Issue: Multitarget Therapeutics for Neurodegenerative Diseases

PROGETTI DI RICERCA FINANZIATI

F-INTERDX, Università di Siena – **45.000€**. *Valorisation of Solid Waste from Sheep industry for a chemically circular and sustainable approach to metal-catalyzed industrial processes* – **ValorWasteS**. PI: Dr Samuele Maramai.

PNRR Project SOLE-H2 - Produzione diffusa fotoattivata di idrogeno verde tramite materiali e processi sostenibili - CUP F57G25000080006, M2C2-3.5. PI: Prof.ssa Adalgisa Sinicropi

F-New Frontiers, Università di Siena – **20.000€**. *Bioconjugates and XRay Activated Prodrugs Charged with DNA Damage Repair Inhibitors: Precision Oncology Strategies for Health Care 4.0,* **BIXREP**. PI: Dr Samuele Maramai.

PNRR Project MNESYS - Partnership con Alfasigma spa - **100.000€**. – *A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022).* PI@Unisi: Dr Samuele Maramai.

PRIN PNRR AntiReTub: An ANTIbody drug conjugate approach to face multidrug REstistant TUBerculosis - Prot. 20227MP3CW_002 Missione 4 Componente 2 (M4C2). PI: Prof.ssa Elena Petricci.

PUBBLICAZIONI

Documenti: 44; *h*-Index: 17; Citations: 850 (Scopus 17/07/26)

44. Neuberger A., Romeo I., Aiello F., Alekseev A., **Maramai S**.*, et al. *Design, synthesis and structural mechanism of action of TRPV1 agonist MSP20 with long-lasting analgesic effect*. Nat Commun. **2026**, doi: 10.1038/s41467-026-74972-3.

43. Zurzolo S., Romagnoli G., Braconi D., Signori G., Ruggirello M., Truglio G., Calamante M., **Maramai S**., et al. *From Waste to Functional Biomicroreactors: Exploration of Wool-Based Stimuli-Triggered Reversible Pickering Emulsions for Transition Metal Catalysis in Water*. ACS Sustainable Chem. Eng. **2026**, 14 (26), 11680–11694.

42. Ciccone V., Cecchin C., Frosini M., Saletti M., **Maramai S**., et al. *VA1213, a selective COX-2 inhibitor, exhibits antitumor activity by suppressing EGFR, AKT, and ERK1/2 phosphorylation*. Eur J Pharm Sci. **2026**, 219, 107422.

41. Corallo A.A., **Maramai S.**, et al. *Targeting TRPA1 with Novel Synthetic Compounds Based on Different Scaffolds to Reduce Acute and Chronic Pain*. Int J Mol Sci. **2026**, 27 (4), 1716.

40. Saletti M., Paolino M., Venditti J., Giuliani G., Rossi A., D'Avino D., Perna S., Varfaj I., Sardella R., Macchiarulo A., **Maramai S**., et al. *Design, Synthesis, and Biological Characterization of Macromolecular Ester Prodrugs of a Selective Cyclooxygenase-2 Inhibitor*. ChemMedChem. **2025**, 20 (24), e202500691.

39. **Maramai S**.*, et al. *Drug enteric metabolism in gut microbiota-brain crosstalk*. Life Sci. **2025**, 15 (383), 124075.

38. Cazzola J., Talpo F., Faravelli G., Donati C., **Maramai S**., et al. *Evaluation of a New Riluzole-Based Compound VA945 on Sodium and Potassium Conductances Expressed by SH-SY5Y- Derived Neurons*. J Neurochem. **2025**, 169 (11), e70280.

37. Poggialini F., Governa P., Vagaggini C., **Maramai S**., et al. *Light-mediated activation/deactivation control and in vitro ADME-Tox profiling of a donepezil-like Dual AChE/MAO-B Inhibitor*. Eur J Pharm Sci., **2025**, 209, 107066.

36. **Maramai S**.*, et al. *Indole-2-Carboxamide as an Effective Scaffold for the Design of New TRPV1 Agonists*. Molecules, **2025**, 30 (3), 721.

35. Paolino M., Saletti M., Venditti J., Castriconi F., Giuliani G., **Maramai S**., et al. *Use of imidazo[1,5-a]quinoline scaffold as the pharmacophore in the design of bivalent ligands of central benzodiazepine receptors*. Bioorg. Med. Chem., **2025**, 117, 118006.

34. Tassone G., **Maramai S**.*, et al. *Exploiting the bile acid binding protein as transporter of a Cholic Acid/Mirin bioconjugate for potential applications in liver cancer therapy.* Sci. Rep., **2024**, 14 (1), 22514.

33. **Maramai S**. et al. *Novel multitarget directed ligands inspired by riluzole: A serendipitous synthesis of substituted benzo[b][1,4]thiazepines potentially useful as neuroprotective agents*. Bioorg. Med. Chem., **2024**, 1121, 117872.

32. Butini S., Grether U., Jung K. M., Ligresti A., Allarà M., Postmus A. G. J., **Maramai S**., et al. *Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization*. J. Med. Chem., **2024**, 67 (3), 1758-1782.

31. Valentini F., Di Erasmo B., Ciancuti C., Rossi S., **Maramai S**., et al. *Macroreticular POLITAG-Pd(0) for the waste minimized hydrogenation/reductive amination of phenols using formic acid as hydrogen source*. Catalysis Today, **2023**, 424, 113833.

30. Romeo I., Brizzi A., Pessina F., Ambrosio F. A., Aiello F., Belardo C., Carullo G., Costa G., De Petrocellis L., Frosini M., Luongo L., **Maramai S**.* et al. *In Silico-Guided Rational Drug Design and Synthesis of Novel 4-(Thiophen-2-yl)butanamides as Potent and Selective TRPV1 Agonists*. J. Med. Chem., **2023**, *66* (10), 6994.

29. Brizzi A.[#] **Maramai S**.[#] et al. *Lipoic/Capsaicin-Related Amides: Synthesis and Biological Characterization of New TRPV1 Agonists Endowed with Protective Properties against Oxidative Stress*. Int. J. Mol. Sci. **2022**, 23 (21), 13580.

28. Tassone G.; Mazzorana M.; Mangani S.; Petricci E.; Cini E.; Giannini G.; Pozzi C.; **Maramai S**. *Structural Characterization of Human Heat Shock Protein 90 N-Terminal Domain and Its Variants K112R and K112A in Complex with a Potent 1,2,3-Triazole-Based Inhibitor*. Int. J. Mol. Sci. **2022**, 23, 9458.

27. Micheli L.[#]; **Maramai S.**[#] et al. *Inhibition of Monoacylglycerol Lipase by NSD1819 as an Effective Strategy for the Endocannabinoid System Modulation against Neuroinflammation-Related Disorders*. Int. J. Mol. Sci. **2022**, 23, 8428.

26. Petricci E., Zurzolo S., Matassini C., **Maramai S**. et al. *An Intramolecular Hydroaminomethylation-Based Approach to Pyrrolizidine Alkaloids under Microwave-Assisted Heating*. Molecules **2022**, 27, 4762.

25. Manetti F., Maresca L., Crivaro E., Pepe S., Cini E., Singh S., Governa P., **Maramai S**. et al. *Quinolines and Oxazino-quinoline Derivatives as Small Molecule GLI1 Inhibitors Identified by Virtual Screening*. ACS Med. Chem. Lett. **2022**, 13, 1329-1336

24. Saletti M.[#]; **Maramai S.**[#] et al. *Novel analgesic/anti-inflammatory agents: 1,5-Diarylpyrrole nitrooxyethyl sulfides and related compounds as Cyclooxygenase-2 inhibitors containing a nitric oxide donor moiety endowed with vasorelaxant properties.* Eur. J. Med. Chem., **2022**, 241, 114615

23. Paolino M., Rullo M.[#], **Maramai S**.[#], et al. *Design, synthesis and biological evaluation of light-driven on–off multitarget AChE and MAO-B inhibitors.* RSC Med. Chem., **2022**,13, 873-883

22. Brizzi A., Trezza A., Spiga O., **Maramai S**., et al. *2-Hydroxy-5-(3,5,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl (E)-3-(4-hydroxy-3-methoxyphenyl)acrylate: Synthesis, In Silico Analysis and In Vitro Pharmacological Evaluation*. Molbank, **2021**, 2021(3), M1258.

21. Campiani G., Cavella C., Osko J. D., Brindisi M., Relitti N., Brogi S., Saraswati P., Federico S., Chemi G., **Maramai S**., et al. *Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors*. J. Med. Chem., **2021**, *64*, 9960−9988

20. Migliorini F., Dei F., **Maramai S**., et al. *Micellar catalysis for sustainable hydroformylation*. ChemCatChem, **2021,** *13***,** 2794 –2806.

19. **Maramai S**.*, Brindisi, M. *Targeting Endocannabinoid Metabolism: An Arrow with Multiple Tips Against Multiple Sclerosis*. ChemMedChem, **2020**,*15,* 1985–2003

18. **Maramai S**.*, et al. *Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations.* BioMed Research International, **2020**, Article ID 5120230.

17. **Maramai S**.*, et al. *Subtype selective γ-Aminobutyric Acid Type A Receptor ($GABA_AR$) modulators Acting at the Benzodiazepine Binding Site: An Update*. J. Med. Chem., **2020**, 63 (7), 3425-3446.

16. Benchekroun M., **Maramai S**. *Multitarget-Directed Ligands for neurodegenerative diseases: real opportunity or blurry mirage?* Future Medicinal Chemistry, **2019**, 11 (4), 261–263

15. Brindisi M., [#]Borrelli G., [#]Brogi S., [#]Grillo A., [#]**Maramai S**., et al. *Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain*, ChemMedChem, **2018**, 13, 2090-2103.

14. Brogi S., Brindisi M., Butini S., Kshirsagar G., **Maramai S**., et al. *AMPA and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements, Structural and Biological Investigation.* J. Med. Chem., **2018**, 61 (5), 2124-2130.

13. Brogi S., **Maramai S**., et al. *Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation.* ChemMedChem, **2017**, 12, 2074-2085.

12. **Maramai S**., et al. *Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases*. Front. Neurosci., **2016**, 10:451.

11. Brindisi M., Cavella C., Brogi S., Nebbioso A., Senger J., **Maramai S**., et al, *Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies*. Future Med Chem. **2016,** 8 (13), 1573-87.

10. Brindisi M., **Maramai S**., et al. *Development of novel cyclic peptides as pro-apoptotic agents*. Eur. J. Med. Chem., 117, **2016**, 301-320

9. Brindisi M., **Maramai S**., et al. *Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.* J. Med. Chem., **2016**, 59 (6), 2612–2632.

8. Brindisi M., Brogi S., **Maramai S**., et al. *Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition*. RSC Adv., **2016**, 6 (69), 64651-64664.

7. Brindisi M.[#], **Maramai S**.[#], et al, *Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of Pretubulysin and analogues*. Tetrahedron Letters 57, **2016**, 920–923.

6. Brogi S., Butini S., **Maramai S**., et al. *Disease modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation*. CNS Neuroscience & Therapeutics 20, **2014**, 624–632.

5. Butini S., Brindisi M., Brogi S., **Maramai S**., et al. *Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation*. ACS Med. Chem. Lett., **2013**, 4 (12), 1178-1182.

4. Butini S., Gabellieri E., Brindisi M., Giovani S., **Maramai S**., et al. *A stereoselective approach to peptidomimetic BACE1 inhibitors*. Eur. J. Med. Chem., 70, **2013**, 233-247

3. Butini S., Gemma S., Brindisi M., **Maramai S**., et al. *Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties.* Bioorg. Med. Chem. Lett. 23, **2013**, 492–495.

2. Butini S., Brindisi M., Gemma S., Minetti P., Cabri W., Gallo G., Vincenti S., Talamonti E., Borsini F., Caprioli A., Stasi M. A., Di Serio S., Ros S., Borrelli G., **Maramai S**., et al. *Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases*. J. Med. Chem., **2012**, *55* (15), 6898–6915.

1. Venskutonité R.; Butini S.; Sanna Coccone S.; Gemma S.; Brindisi M.; Kumar V.; Guarino E.; **Maramai S**., et al. *Selective Kainate Receptors (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H, 3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization*. J. Med. Chem., **2011**, *54* (13), 4793-4805.

CAPITOLI DI LIBRO

3. Tassone G., Carradori S., **Maramai S**.*, D'Agostino I. Catechol-O-methyltransferase (COMT). Metalloenzymes: From Bench to Bedside, **2023**, 63 - 81

2. Giordani A., Poce G., Consalvi S., **Maramai S**., et al. Nitric Oxide in Health and Disease: Therapeutic Applications in Cancer and Inflammatory Disorders – **2023**. Chapter 3: Therapeutic potential for coxib-nitric oxide releasing hybrids in cancer treatment.

1. **Maramai S**.*, Taddei M*. Sustainable Organic Synthesis: Tools and Strategies – **2021** Chapter 18: Microwave Irradiation.

BREVETTI

Baek K. S., Khoo J. H., Choi S., Park Y. W., Ward S., Le Grand D., West R., Turner P., **Maramai S**., Reuillon T. Preparation of Substituted 1,2-Diaminoheterocyclic Compound Derivatives and Their Use as Pharmaceutical Agents. **WO2022260441A1**

Maramai S., Mazzacani A., Paradowski M., Ward S. 2-Oxo-dihydroquinoline-3-carboxamide Derivatives as GABA Type A Receptor Modulators. **WO2022079432A1**

CONGRESSI E CONFERENZE

18 congressi, 11 comunicazioni orali, 4 presentazioni poster

XLII CDCO – Convegno Nazionale della Divisione di Chimica Organica della Società Chimica Italiana. 21-25 Settembre 2025, Cagliari. **Poster Presentation**: *Synthesis and characterization of small molecule-drug conjugates for targeted drug delivery.*

XXVII Congresso Nazionale della Società Chimica Italiana – 26-30 Agosto 2024, Milano. **Poster Presentation**: *Synthesis and characterization of small molecule-drug conjugates for targeted drug delivery.*

New frontiers in synthetic chemistry 2023 – The Royal Society of Chemistry. 09 Novembre 2023, Londra.

XXVIII NMMC - National Meeting on Medicinal Chemistry, 17-20 Settembre 2023, Chieti. **Oral Communication**: *1,4,5-Trisubstituted 1,2,3-triazole derivatives as HSP90 inhibitors: synthesis, evaluation and structural characterization*.

XLI CDCO – Convegno Nazionale della Divisione di Chimica Organica della Società Chimica Italiana. 10-14 Settembre 2023, Roma. **Oral Communication**: *Efficient click chemistry towards 1,4,5-trisubstituted 1,2,3-triazole derivatives: synthesis, evaluation, and structural characterization of novel Hsp90 inhibitors*

ACS Spring 2023 – 26-30 Marzo 2023, Indianapolis. **Oral Communication**: *Efficient click chemistry towards 1,4,5-trisubstituted 1,2,3-triazole derivatives: synthesis, evaluation, and structural characterization of novel Hsp90 inhibitors*

XL CDCO – Convegno Nazionale della Divisione di Chimica Organica della Società Chimica Italiana. 11-15 Settembre 2022, Palermo. **Oral Communication**: *Exploiting the* β*-lactam scaffold for the synthesis of biologically active compounds*

ACS Spring 2022 – 20-24 Marzo 2022, San Diego. **Oral Communication**: *Selective blockers of 2-arachidonoylglycerol degradation useful for the treatment of neurodegenerative and neuroinflammatory disorders*

XXVII Congresso Nazionale della Società Chimica Italiana – 14-23 Settembre 2021, online meeting. **Poster Presentation**: *Metal Catalysis for Sustainable Transformations in Aqueous Micellar Conditions*

13° NPCF - Young Medicinal Chemists' Symposium, 26-29 Aprile 2021, Firenze. **Oral Communication**: *Subtype Selective γ-Aminobutyric Acid Type A Receptors ($GABA_AR$) Modulators Acting at the Benzodiazepine Binding Site.*

XXVI NMMC - National Meeting on Medicinal Chemistry, 16-19 Luglio 2019, Milano. **Oral Communication**: *Design, Synthesis and Pharmacological Characterization of Selective Blockers of 2-Arachidoylglycerol Degradation*

XXIII NMMC - National Meeting on Medicinal Chemistry, 9° NPCF - Young Medicinal Chemists Symposium, September 06^{th}-09^{th}, 2015, Fisciano (SA) – **Poster Presentation**: *Development of Cyclic Peptides as Pro-Apoptotic Agents*

8° NPCF - Young Medicinal Chemists' Symposium, 10-12 Giugno 2014, Parma. **Oral Communication**: *Disease Modifying Anti-Alzheimer Drugs. Inhibitors of Human Cholinesterases Interfering with* β*-Amyloid Aggregation*

XXI NMMC - National Meeting on Medicinal Chemistry, 17-20 Luglio 2012, Palermo. **Oral Communication**: *Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases*

III Italian-Hispano-Portuguese Workshop on Ion Channels and Transporters, 7-10 Luglio 2011, Imola. **Oral Communication**: *Selective Kainate Receptors (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization*

5° NPCF - Young Medicinal Chemists' Symposium, 28-30 Marzo 2011, Trieste. **Oral Communication**: *Selective Kainate Receptors (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modelling, and Pharmacological and Biostructural Characterization*

4° NPCF - Young Medicinal Chemists' Symposium, 6-7 Maggio 2010, Pula (CA)

3° NPCF - Young Medicinal Chemists' Symposium, 13-14 Febbraio 2009, Castelvecchio Pascoli (LU)

COMITATI SCIENTIFICI E ORGANIZZATORI

ScienceS@SI – Scientific Symposium at Unisi, Second Edition, July 21st, 2022 –. Sciences@SI Scientific and Organizing Committee. http://www.congressi.unisi.it/sciencesatsi

ScienceS@SI – Scientific Symposium at Unisi, Summer Edition, July 16th, 2021 – Sciences@SI Scientific and Organizing Committee. http://www.congressi.unisi.it/sciencesatsi

8° European Workshop in Drug Synthesis EWDSy, May 21st, 2021, Siena. EWDSy Organizing Committee. http://www.congressi.unisi.it/ewdsy

Siena, 23/07/2026